Background {#Sec1}
==========

*Ixodes holocyclus*, also known as the paralysis tick in Australia, causes tick paralysis in domestic animals, a potentially-lethal disease seen predominantly in dogs and cats \[[@CR1]--[@CR3]\], horses \[[@CR4]--[@CR6]\] and humans \[[@CR7]--[@CR9]\]. *Ixodes holocyclus* is widely distributed along the eastern coastal regions of Australia from North Queensland to Lakes Entrance of Victoria \[[@CR1], [@CR10]--[@CR12]\]. The majority of cases of tick paralysis in dogs are reported during spring to early summer due to favorable climate \[[@CR1], [@CR11]\]. *Ixodes holocyclus* is suspected as a vector for transmission of *Borrelia burgdorferi* (*sensu stricto*) \[[@CR13]\] and *Rickettsia australis* \[[@CR14], [@CR15]\] in humans, but it is rarely reported as a vector for transmission of other pathogens in domestic animals.

Tick paralysis is characterised by progressive ascending lower motor neuron (LMN) flaccid paralysis caused by the neurotoxin produced in the salivary glands of the female *I. holocyclus* \[[@CR3], [@CR16]\]. Clinical manifestations of tick paralysis have been previously reviewed and well documented and include flaccid paralysis, cardio-pulmonary complications and sometimes death \[[@CR3], [@CR17], [@CR18]\]. Typically, the onset of clinical signs usually does not occur until 4 or 5 days after tick attachment \[[@CR3], [@CR17], [@CR19]\]. This coincides with a sudden increase in the salivary toxin secretions which occur during the later stages of tick infestations \[[@CR3], [@CR16]\]. The duration of feeding, rate of growth and release of toxins however can vary depending on the age of the ticks and favorable ambient temperature and humidity \[[@CR20]\]. The longer the duration of attachment, the greater the potential risk of paralysis, thus the sooner an attached tick can be removed, the lower the risk of paralysis \[[@CR17], [@CR19]\]. Therefore, an acaricide with a fast speed of kill is critical in removing any pre-existing ticks and minimising the risk of morbidity and mortality due to tick paralysis \[[@CR21]\].

Treatment of tick paralysis typically centers around removal of attached ticks, the neutralization of toxins, the control of clinical manifestations of tick paralysis and the treatment of any anaphylactic reactions due to the administration of tick anti-sera \[[@CR22]\]. Successful treatment outcomes also depend on locating and removing all the attached ticks on the dogs followed by the administration of an acaricidal agent \[[@CR23]\]. A routine tick search, even by an experienced person, may be unsuccessful in locating all ticks, even in the common predilection sites \[[@CR20]\], since ticks can be hidden in areas such as the nostril, inside the anus and ear canals, hence an acaricide with a wider systemic distribution should be the preferred choice of treatment. Systemic formulations like the new class of isoxazolines offer wider distribution to all anatomical sites in the body \[[@CR21]\] and are therefore able to provide more reliable efficacy, unlike the topical counterparts \[[@CR23]\] which may not reach all the anatomical sites.

The introduction of isoxazolines such as sarolaner, afoxolaner and fluralaner has resulted in an improvement in tick control in dogs in recent times. Sarolaner, a pure form of S-entamioner, is a potent ectoparaciticide \[[@CR24]\] with a broad spectrum of activity against different tick species \[[@CR25], [@CR26]\], including the Australian paralysis tick, *I. holocyclus* (Zoetis, unpublished data).

In this laboratory study, the speed of kill of sarolaner (Simparica^®^) and afoxolaner (Nexgard^®^) was evaluated against existing *I. holocyclus* infestations and weekly re-infestations for a period of 5 weeks after treatment with a single dose.

Methods {#Sec2}
=======

The study was a blinded, negative-controlled, randomized laboratory efficacy design conducted in New South Wales, Australia. Study procedures were in accordance with the World Association for the Advancement of Veterinary Parasitology (WAAVP) guidelines for evaluating the efficacy of parasiticides for the treatment, prevention and control of flea and tick infestation on dogs and cats \[[@CR27]\] and complied with the principles of Good Clinical Practice \[[@CR28]\]. The protocol was reviewed and approved by the Vet^x^ Research Animal Ethics Committee, NSW. Blinding of the study was assured through the separation of functions. All personnel conducting observations, or performing infestations and counts were blinded to treatment allocation.

Animals {#Sec3}
-------

Twenty-four (24) male and female, Foxhound dogs from 1 to 9 years of age and weighing from 30.1 to 46.9 kg were used in the study. Each dog was individually identified by a unique electronic transponder and had undergone an adequate wash-out period to ensure that no residual ectoparasiticide efficacy remained from any previously administered treatments. This was confirmed by the tick carrying capacity test results that showed all enrolled dogs had ≥ 21 ticks. Dogs were individually housed in indoor runs such that no physical contact was possible between them and they were acclimatized to these conditions for at least 7 days prior to treatment. Dogs were fed an appropriate maintenance ration of a commercial dry canine feed for the duration of the study. Water was available *ad libitum*. All dogs were given a physical examination to ensure that they were in good health at enrollment and suitable for inclusion in the study. General health observations were performed twice daily throughout the study.

Design {#Sec4}
------

The study followed a randomized complete block design, with pairs of dogs as the experimental unit. Dogs enrolled in the study were immunised to the tick toxin- holocylotoxin as described previously \[[@CR29]\] and selected based on acceptable results (tick counts of  ≥ 21) to the tick carrying capacity test performed on Day -7. Prior to treatment, dogs were ranked according to pre-treatment body weights into four blocks of six (three pairs of dogs). Within each block, one pair of dogs was randomly allocated to treatment with placebo, sarolaner, or afoxolaner. There were eight dogs per treatment group.

Treatment {#Sec5}
---------

Body weights collected on Day -5 were used to determine the appropriate dose to be administered. On Day 0, dogs received either a placebo tablet, Simparica^®^ (sarolaner) at the recommended dose of 2 mg/kg (range: 2 to 4 mg/kg), or NexGard^®^ (afoxolaner) as per label directions (2.7 to 6.9 mg/kg). All doses were administered by hand pilling to ensure accurate and complete dosing. Each dog was observed for at least 2 min after treatment to ensure the dose was swallowed.

Tick infestation and assessment {#Sec6}
-------------------------------

The unfed adult female *I. holocyclus* ticks were collected from the Northern Rivers region of New South Wales, Australia approximately 2 months prior to the start of the study. The ticks were stored in dark conditions at around 12 °C and high humidity \[[@CR29]\]. Tick infestations were performed on Days -7 (host suitability), -1, 7, 14, 21, 28 and 35. Prior to each infestation, dogs were examined to ensure they were free of ticks. Each dog was infested with 30 viable unfed female ticks at pre-defined locations (head, shoulders, dorsal midline of the body) on the dogs as described previously \[[@CR29]\]. For Day -1 infestation, tick counts were performed at 8, 12, 24 and 48 h after treatment on Day 0 and all other tick counts were performed at 12, 24 and 48 h after each weekly infestation. Tick assessments at 8 (only on Day 0), 12 and 24 h time points were performed without removing the ticks from the dogs. After counting at the 48 h time point, all ticks were removed. Ticks were characterised as described previously \[[@CR29]\] except moribund ticks were recorded in a separate category and included in the live counts in this study for the efficacy calculations.

Statistical analysis {#Sec7}
--------------------

The primary outcome measure was live tick counts. Data for post-treatment live (free plus attached) tick counts were summarized with arithmetic (AM) and geometric (GM) means by treatment group and time point. Tick counts were transformed by the log~e~(count + 1) transformation prior to analysis in order to stabilize the variance and normalize the data. Using the PROC MIXED procedure (SAS 9.3, SAS Institute Inc., Cary, NC, USA), transformed counts were analyzed using a mixed linear model for repeated measures for the 12, 24 and 48 h time points separately. The fixed effects were treatment, time point and the interaction between time point and treatment. The random effects included block, pair, animal, block by treatment by time point interaction, and error. The data for the 8 h time point (Day 0 only) were analysed with terms including the fixed effect of treatment group and the random effects of block, pair and error. Testing was two-sided at the significance level α = 0.05, with tests based on contrasts between treatment least squares means from the fitted models.

The assessment of efficacy for live ticks was based on the percent reduction in the AM and GM live tick counts for the treated groups relative to placebo, as suggested by the most recent guidelines of the WAAVP for systemic acaricides \[[@CR27]\], and was calculated using Abbott's formula:$$\documentclass[12pt]{minimal}
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As the distribution of parasite counts within each group was likely be skewed, comparison between groups was primarily based on GM live tick counts \[[@CR27]\].

Results {#Sec8}
=======

There were no treatment-related adverse events during the study. Placebo-treated dogs maintained good tick infestations throughout the study with individual tick counts ranging from 15 to 30 (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}).Table 1Mean live *Ixodes holocyclus* counts and efficacy relative to placebo at 8, 12, 24 and 48 h after treatment for dogs treated with a single oral dose of sarolaner or afoxolaner on Day 0TreatmentTick counting time points post-treatment8 h12 h24 h48 hPlaceboRange21--2820--2819--2819--30Arithmetic mean (AM)24.1324.2523.6323.75Geometric mean GM)^a^24.0024.1323.4723.53SarolanerRange0--130--80--00--0Arithmetic mean (AM)5.131.6300AM Efficacy (%)78.8793.30100100Geometric mean (GM)^a^3.320.7600GM Efficacy (%)86.1796.87100100Test statistic *vs* placebo*t* ~(9)~ = 5.02*t* ~(8)~ = 8.65*t* ~(34)~ = 17.31*t* ~(17)~ = 58.45*P*-value *vs* placebo0.0007\< 0.0001\< 0.0001\< 0.0001AfoxolanerRange10--281--130--20--0Arithmetic mean (AM)20.135.000.380AM Efficacy (%)17.0179.3898.41100Geometric mean (GM)^a^18.893.630.250GM Efficacy (%)21.2884.9598.93100Test statistic *vs* placebo*t* ~(9)~ = 0.65*t* ~(8)~ = 6.24*t* ~(46)~ = 11.78*t* ~(17)~ = 58.45*P*-value *vs* placebo0.53020.0003\< 0.0001\< 0.0001Test statistic *vs* sarolaner*t* ~(9)~ = 4.36*t* ~(15)~ = 2.40*t* ~(70)~ = 0.74*t* ~(17)~ = 0.00*P*-value *vs* sarolaner0.00180.03030.46221.0000^a^ *P*-values are based on comparison of geometric means Table 2Mean live *Ixodes holocyclus* counts and efficacy relative to placebo at 12 h after weekly re-infestations for dogs treated with a single oral dose of sarolaner or afoxolaner on Day 0TreatmentDay of study714212835PlaceboRange16--2822--2817--2619--2723--28Arithmetic Mean (AM)21.7525.2523.7523.1325.13Geometric Mean (GM)^a^21.4425.1623.5622.9925.09SarolanerRange0--120--100--182--212--16Arithmetic mean (AM)3.003.004.8810.758.75AM Efficacy (%)86.2188.1279.4753.5165.17Geometric mean (GM)^a^1.672.263.119.157.50GM Efficacy (%)92.2091.0386.7860.2170.11Test statistic *vs* placebo*t* ~(8)~ = 6.26*t* ~(8)~ = 8.50*t* ~(8)~ = 5.41*t* ~(9)~ = 3.77*t* ~(8)~ = 4.97*P*-value *vs* placebo0.0002\< 0.00010.00070.00480.0012AfoxolanerRange2--167--2010--2215--2816--27Arithmetic mean (AM)9.6312.1317.6322.0021.00AM Efficacy (%)55.7551.9825.794.8616.42Geometric mean (GM)^a^8.3611.4917.0321.6620.78GM Efficacy (%)61.0154.3127.695.7817.17Test statistic *vs* placebo*t* ~(9)~ = 3.85*t* ~(10)~ = 6.26*t* ~(15)~ = 2.65*t* ~(17)~ = 0.67*t* ~(15)~ = 2.30*P*-value *vs* placebo0.0042\< 0.00010.01820.51380.0366Test statistic *vs* sarolaner*t* ~(13)~ = 3.16*t* ~(10)~ = 5.07*t* ~(9)~ = 4.37*t* ~(9)~ = 3.44*t* ~(8)~ = 4.10*P*-value *vs* sarolaner0.00770.00040.00210.00700.0033^a^ *P*-values are based on comparison of geometric means Table 3Mean live *Ixodes holocyclus* counts and efficacy relative to placebo at 24 h after weekly re-infestations for dogs treated with a single oral dose of sarolaner or afoxolaner on Day 0TreatmentDay of study815222936PlaceboRange17--2720--2815--2619--2619--26Arithmetic Mean (AM)21.0024.1323.7522.2522.88Geometric Mean (GM)^a^20.7023.9523.4422.1322.78SarolanerRange0--60--10--30--30--3Arithmetic mean (AM)1.750.250.381.250.75AM Efficacy (%)91.6798.9698.4294.3896.72Geometric mean (GM)^a^1.260.190.190.960.49GM Efficacy (%)93.9399.2199.1995.6797.86Test statistic *vs* placebo*t* ~(34)~ = 12.26*t* ~(34)~ = 16.48*t* ~(34)~ = 16.37*t* ~(34)~ = 13.37*t* ~(34)~ = 15.01*P*-value *vs* placebo\< 0.0001\< 0.0001\< 0.0001\< 0.0001\< 0.0001AfoxolanerRange0--50--10--60--50--8Arithmetic mean (AM)2.000.252.751.752.75AM Efficacy (%)90.4898.9688.4292.1387.98Geometric mean (GM)^a^1.410.191.781.141.85GM Efficacy (%)93.1799.2192.4294.8791.89Test statistic *vs* placebo*t* ~(46)~ = 8.70*t* ~(46)~ = 12.06*t* ~(46)~ = 8.62*t* ~(46)~ = 9.44*t* ~(46)~ = 8.41*P*-value *vs* placebo\< 0.0001\< 0.0001\< 0.0001\< 0.0001\< 0.0001Test statistic *vs* sarolaner*t* ~(70)~ = 0.22*t* ~(70)~ = 0.00*t* ~(70)~ = 2.80*t* ~(70)~ = 0.29*t* ~(70)~ = 2.14*P*-value *vs* sarolaner0.82471.00000.00660.77570.0356^a^ *P*-values are based on comparison of geometric means Table 4Mean live *Ixodes holocyclus* counts and efficacy relative to placebo at 48 h after weekly re-infestations for dogs treated with a single oral dose of sarolaner or afoxolaner on Day 0TreatmentDay of study916233037PlaceboRange17--2620--2815--2621--2719--26Arithmetic mean (AM)21.0024.1322.0022.8822.25Geometric mean (GM)^a^20.7923.9821.6922.8022.15SarolanerRange0--00--20--20--30--1Arithmetic mean (AM)00.380.501.250.25AM Efficacy (%)10098.4597.7394.5498.88G. mean (GM)^a^00.250.321.030.19GM Efficacy (%)10098.9598.5495.4899.15Test statistic *vs* placebo*t* ~(19)~ = 54.50*t* ~(25)~ = 20.30*t* ~(19)~ = 13.13*t* ~(23)~ = 12.78*t* ~(26)~ = 21.67*P*-value *vs* placebo\< 0.0001\< 0.0001\< 0.0001\< 0.0001\< 0.0001AfoxolanerRange0--00--10--40--20--1Arithmetic mean (AM)00.131.500.380.25AM Efficacy (%)10099.4893.1898.3698.88G. mean (GM)^a^00.091.280.250.19GM Efficacy (%)10099.6294.1298.9099.15Test statistic *vs* placebo*t* ~(19)~ = 54.50*t* ~(25)~ = 21.23*t* ~(19)~ = 10.60*t* ~(23)~ = 15.29*t* ~(26)~ = 21.67*P*-value *vs* placebo\< 0.0001\< 0.0001\< 0.0001\< 0.0001\< 0.0001Test statistic *vs* sarolaner*t* ~(19)~ = 0.00*t* ~(25)~ = 0.93*t* ~(19)~ = 2.53*t* ~(23)~ = 2.51*t* ~(26)~ = 0.00*P*-value *vs* sarolaner1.00000.36060.02040.01951.0000^a^ *P*-values are based on comparison of geometric means

Against an existing infestation, at the 8 and 12 h time points, treatment with sarolaner resulted in significantly lower GM tick counts compared to both placebo (*P* ≤ 0.0007) and afoxolaner treated dogs (*P* ≤ 0.0303). There was no significant difference between the GM live tick counts at 8 h for the afoxolaner and placebo-treated dogs (*P* = 0.5302). Efficacy of sarolaner against an existing infestation was 86.2 and 96.9% compared with that of afoxolaner which had efficacy of 21.3 and 85.0% at 8 and 12 h time points respectively. Efficacy of sarolaner and afoxolaner reached 100% at 24 and 48 h post-treatment respectively (Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Percent efficacy based on geometric mean counts relative to placebo at 8, 12, 24 and 48 h after treatment for dogs treated with a single oral dose of sarolaner or afoxolaner on Day 0

Against subsequent weekly infestations at the 12 h time points, treatment with sarolaner resulted in significantly lower GM tick counts compared to both placebo- (*P* ≤ 0.0048) and afoxolaner-treated dogs (*P* ≤ 0.0077) on all Days (7, 14, 21, 28 and 35). Efficacy of sarolaner at the 12 h time points following weekly re-infestations ranged from 60.2 to 92.2% compared to 5.8 to 61.0% in the afoxolaner treated dogs (Table [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Percent efficacy based on geometric mean counts relative to placebo at 12, 24 and 48 h after weekly post-treatment re-infestations of *Ixodes holocyclus* for dogs treated with a single oral dose of sarolaner or afoxolaner on Day 0

Against subsequent weekly infestations at the 24 h time points on days 22 and 36, sarolaner-treated dogs had significantly lower GM tick counts than afoxolaner-treated dogs (*P* ≤ 0.0356). On Days 8, 15, 22, 29 and 36, treatment with sarolaner and afoxolaner resulted in significantly lower GM tick counts than placebo (*P* ≤ 0.0001). At 24 h following weekly re-infestations, efficacy of sarolaner ranged from 93.9 to 99.2% compared to 91.9 to 99.2% in the afoxolaner-treated dogs (Table [3](#Tab3){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}).

Against weekly infestations, at the 48 h time points treatment with sarolaner and afoxolaner resulted in significantly lower GM tick counts than placebo (*P* ≤ 0.0001) and efficacy (GM) of sarolaner and afoxolaner treated dogs were ≥ 95.5% and ≥ 94.1% respectively (Table [4](#Tab4){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}).

Discussion {#Sec9}
==========

A single dose of sarolaner resulted in the rapid reduction of an existing infestation of live *I. holocyclus* ticks with an efficacy of 86.2% at 8 h and 96.9% at 12 h post-treatment and the rapid kill of re-infestations for 5 weeks after treatment within 12 h of attachment with an efficacy of  ≥ 60.2%. Although the onset of tick paralysis typically does not occur until day 4 or 5 after tick attachment, the sooner an attached tick can be killed, the lower the risk of paralysis \[[@CR3], [@CR17], [@CR19]\], especially those pre-existing ticks that have already been on the dogs for 3--4 days prior to treatment. The rapid speed of kill of sarolaner as early as 8 h against an existing infestation will provide faster removal of attached ticks, thereby minimising the risk of tick paralysis. Similar faster speed of kill of sarolaner has also been demonstrated against other *Ixodes* tick species such as *Ixodes scapularis* and *Ixodes ricinus* \[[@CR30], [@CR31]\]. The faster speed of kill and persistent efficacy of sarolaner will provide excellent overall efficacy against *I. holocyclus* for up to 5 weeks.

Conclusions {#Sec10}
===========

Sarolaner had a significantly faster speed of kill at both 8 and 12 h compared with afoxolaner against existing infections of paralysis tick and had higher efficacy than afoxolaner at 12 h after re-infestation over 35 days.

The rapid and consistent kill of ticks provided by sarolaner within 24 h after a single oral dose and following weekly re-infestations over 35 days suggests this treatment will provide highly effective, rapid and reliable control of ticks over the entire treatment interval, thereby minimizing the risk of tick paralysis in dogs.

Additional file {#Sec11}
===============

Additional file 1:Comparative *Ixodes holocylcus* individual tick counts. (XLSX 21 kb)
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